Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
12
×
life sciences
national blog main
national top stories
roche
12
×
boston blog main
boston top stories
clinical trials
san francisco top stories
san francisco blog main
cancer
deals
fda
national
novartis
boston
investing
pfizer
amgen
bristol-myers squibb
europe blog main
europe top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
biotech ipos
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
genentech
merck
new york blog main
san diego blog main
san diego top stories
seattle blog main
seattle top stories
What
drug
cancer
fda
medicines
roche
therapy
approval
gene
intended
patients
therapeutics
bio
blueprint
crispr
ipo
medicine
new
research
ret
roundup
team
access
address
advanced
advantages
alliance
analytics
annual
approved
approves
ash
atrophy
bar
barcelona
betting
billion
biofourmis
biopharma
blood
brings
Language
unset
12
×
Current search:
roche
×
unset
×
biotech
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone